CAPREOMYCIN FOR INJECTION

DRAFT PROPOSAL FOR

THE INTERNATIONAL PHARMACOPOEIA

(AUGUST 2010)

DRAFT FOR COMMENT

This document was provided by a quality control expert and was discussed at the recent WHO consultation on specifications for medicines and quality control laboratory issues. Previous comments received have been incorporated into this revised draft. Should you have any comments, please send these to Dr S. Kopp, Manager, Medicines Quality Assurance Programme, Quality Assurance and Safety: Medicines, World Health Organization, 1211 Geneva 27, Switzerland; e-mail: kopp@who.int with a copy to Ms C. Mendy mendyc@who.int by 1 October 2010.

During the past few years we have moved more towards an electronic system for sending out our draft monographs for comment, for convenience and in order to speed up the process. If you do not already receive our documents electronically, please let us have your e-mail address (to bonnyw@who.int) and we will add it to our electronic mailing list.

© World Health Organization 2010
All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations’ concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:
Dr Sabine Kopp, Quality Assurance Programme, Medicines Quality Assurance Programme, Quality & Safety: Medicines (QSM), Department of Essential Medicines and Pharmaceutical Policies (EMP), World Health Organization, CH-1211 Geneva 27, Switzerland. Fax: (41-22) 791 4730; e-mail: kopp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT

QAS/10.358

*International Pharmacopoeia monograph on Capreomycin injection*

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preparation of first draft by laboratory</td>
<td>February 2010</td>
</tr>
<tr>
<td>Discussion of first draft in telephone conference</td>
<td>25 March 2010</td>
</tr>
<tr>
<td>Discussion of the draft monograph in the consultation on specifications for medicines and quality control laboratory issues</td>
<td>10-12 May 2010</td>
</tr>
<tr>
<td>Mailing of draft monograph for comments</td>
<td>August 2010</td>
</tr>
<tr>
<td>Collation of comments received</td>
<td>September-October 2010</td>
</tr>
<tr>
<td>Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations</td>
<td>18-22 October 2010</td>
</tr>
<tr>
<td>Any further action as required</td>
<td>…</td>
</tr>
</tbody>
</table>
Draft proposal for The International Pharmacopoeia  
(August 2010)

CAPREOMYCINI AD INJECTIONEM  
CAPREOMYCIN FOR INJECTION

**Description.** A white or almost white powder.

**Category.** Antituberculosis drug.

**Storage.** Capreomycin for injection should be stored in a well-closed container.

**Labelling.** The designation on the container of capreomycin for injection should state that the active ingredient is in the sulfate form, and the quantity should be indicated in terms of the equivalent amount of capreomycin.

**Additional information.** Strength in the current WHO Model list of essential medicines: 1 g. Strength in the current WHO Model list of essential medicines for children: 1 g. The injection is reconstituted by dilution of Capreomycin powder for injections in Water for injections.

**Requirements**

The powder for injection and the reconstituted injection comply with the monograph for “Parenteral preparations”.

**Definition.** Capreomycin for injection is a sterile powder containing Capreomycin sulfate. It contains not less than 90.0% and not more than 115.0% of the amount of capreomycin stated on the label, taking into account the sum of capreomycins IA, IB, IIA and IIB.

**Identity tests**

- Either tests A and E or tests B, C, D and E may be applied.

A. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from capreomycin sulfate RS or with the reference spectrum of capreomycin sulfate.

B. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R5 as the coating substance and a mixture of 30 volumes of phenol R, 10 volumes of water R and 1 volume of ammonia (~260 g/l) TS as the mobile phase. Apply separately to the plate 4 μl of each of the following two solutions in water R. For solution (A), dissolve a quantity of the powder to obtain a solution containing 10 mg of the test substance per ml. For solution (B), use 10 mg of capreomycin sulfate RS
per ml. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in air. Spray with triketohydrindene/methanol TS and heat the plate for 3 minutes at 120 °C. Examine the chromatogram in daylight.

The spots obtained with solution A correspond in position, appearance, and intensity with those obtained with solution B.

C. Dissolve a quantity of the powder in hydrochloric acid (0.1 mol/l) VS to obtain a solution containing the equivalent of 20 µg of capreomycin per ml. The absorption spectrum of this solution, when observed between 230 nm and 350 nm, exhibits one maximum at about 268 nm.

D. Dissolve a quantity of the powder in sodium hydroxide (0.1 mol/l) VS to obtain a solution containing the equivalent of 20 µg of capreomycin per ml. The absorption spectrum of this solution, when observed between 230 nm and 350 nm, exhibits a major maximum at about 287 nm.

E. A solution of the powder containing the equivalent of 20 mg of capreomycin per ml yields reaction A described under 2.1 General identification tests as characteristic of sulfates.

**Clarity of solution.** A freshly prepared solution of the powder containing the equivalent of 1 g of capreomycin in 10 ml of carbon-dioxide-free water R is clear.

**pH value (1.3).** pH of a solution of the powder containing the equivalent of 0.3 g of capreomycin in 10 ml of carbon-dioxide-free water R, 4.5-7.5.

**Bacterial endotoxins.** Carry out the test as described under 3.4 Test for bacterial endotoxins; contains not more than 0.35 IU of endotoxin per mg of capreomycin.

**Related substances.** Carry out the test as described under 1.14.4 High performance liquid chromatography, using the conditions given under Assay.

Prepare the following solutions using water R as diluent. For solution (1) dissolve a quantity of the powder to obtain a solution containing the equivalent of 2.0 mg of capreomycin per ml. For solution (2) dilute a suitable volume of solution (1) to obtain a concentration of 10 µg of capreomycin per ml.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 268 nm.

Inject 20 µl of solution (1). The test is not valid unless the resolution between the two major peaks corresponding to capreomycin IA and capreomycin IB, with a relative retention of 0.89 and 1, respectively, is at least 2.0. The test is also not valid unless the resolution between the peaks corresponding to capreomycin IIA and capreomycin IIB, with a relative retention of 0.53 and 0.63, respectively, is at least 3.5.

Inject separately 20 µl each of solutions (1) and (2).

In the chromatogram obtained with solution (1), the area of any peak, other than the four major peaks corresponding to capreomycins IA, IB, IIA and IIB, is not greater than 4 times the sum of the areas of the four major peaks obtained with solution (2) (2.0%). The area of not more than one such peak is greater than twice the sum of the areas of the four
major peaks obtained with solution (2) (1.0%). The sum of the areas of all peaks, other than the four major peaks, is not greater than 14 times the sum of the areas of the four major peaks obtained with solution (2) (7.0%). Disregard any peak with an area less than 0.1 times the sum of the areas of the four major peaks in the chromatogram obtained with solution (2) (0.05%).

**Assay**

Carry out the test as described under 1.14.4 High performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with base deactivated particles of silica gel the surface of which has been modified with chemically bonded octadecysilyl groups (5 µm)\(^1\).

The mobile phases for the gradient elution consist of a mixture of Mobile phase A and Mobile phase B, using the following conditions:

- **Mobile phase A:** 5 volumes of acetonitrile R and 95 volumes of phosphate buffer pH 2.3.
- **Mobile phase B:** 15 volumes of acetonitrile R and 85 volumes of phosphate buffer pH 2.3.

Prepare the phosphate buffer pH 2.3 by dissolving 54.4 g of potassium dihydrogen phosphate R in 1500 ml of water R, adjust the pH to 2.3 by adding phosphoric acid (~105 g/l) TS, add 9.4 g of sodium hexanesulfonate R and dilute to 2000 ml with water R.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-25</td>
<td>55 to 52</td>
<td>45 to 48</td>
<td>Linear gradient</td>
</tr>
<tr>
<td>25-40</td>
<td>52</td>
<td>48</td>
<td>Isocratic</td>
</tr>
<tr>
<td>40-60</td>
<td>30</td>
<td>70</td>
<td>Isocratic</td>
</tr>
<tr>
<td>60-70</td>
<td>55</td>
<td>45</td>
<td>Isocratic re-equilibration</td>
</tr>
</tbody>
</table>

Prepare the following solutions using water R as diluent. For solution (1) dissolve a quantity of the powder to obtain a solution containing the equivalent of 2.0 mg of capreomycin per ml. For solution (2) use an amount of capreomycin sulfate RS equivalent to 2.0 mg of capreomycin per ml.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 268 nm.

Inject 20 µl of solution (1). The assay is not valid unless the resolution between the two major peaks corresponding to capreomycin IA and capreomycin IB, with a relative retention of 0.89 and 1, respectively, is at least 2.0. The assay is also not valid unless the resolution between the peaks corresponding to capreomycin IIA and capreomycin IIB, with a relative retention of 0.53 and 0.63, respectively, is at least 3.5.

\(^1\) Hypersil BDS column has been found suitable.
Inject separately 20 µl each of solutions (1) and (2).

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the content of capreomycin (sum of the four peaks corresponding to capreomycins IA, IB, IIA and IIB) from the declared content of capreomycin in capreomycin sulfate RS.

[Note from Secretariat: it is proposed that the ICRS will have its content expressed on the label in terms of capreomycin base and capreomycin sulfate]

***